Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer

Silverstein J, Smick A, Johnson B, Konecny GE. Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Future Oncol. 2025 Jun 12:1-11. doi: 10.1080/14796694.2025.2513848. Epub ahead of print. PMID: 40501444.


Related Posts